Accunea is a medical device business developing novel real-time point-of-care diagnostic and monitoring technologies for clinical transplant centres. Founded by Dr Nick Housby and Dr Robert Learney in March 2017, the two share a belief that real-time functional monitoring has the power to improve many areas of current clinical practice, where a lack of data at the point of care, an inability to perform predictive analysis, and a lack of population-level clinical insights are leading to suboptimal patient outcomes. Dr Nick Housby and Dr Robert Learney have collaborated to build Accunea around the patent-pending RenoSure real-time organ function monitoring technology, initially developed by Dr Learney during his PhD research at Imperial College London.
Accunea seeks to improve confidence and safety when making critical decisions by complementing and enhancing the skills of medical professionals, enabling them to draw upon cutting-edge sensor technology, advanced analytics, and design. Their premier product, RenoSure, is a bedside multi-parameter organ function monitoring device that provides unprecedented capabilities for monitoring organ function and metabolic condition both pre-and-post-transplantation.
We are delighted to move into the Oxford BioEscalator as we start to grow our organisation and begin clinical studies. In this location, we will seek to engage with numerous academic, NHS and commercial entities.
Nick Housby - CEO and Co-Founder of Accunea